N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
Phase 2 N=10 Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
Heart Failure
Primary: Biologic Efficacy: Inflammation Marker - C-Reactive Protein — 2.5; 0.6; 0.6 mg/dL
N/A N=639 Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
Chronic Heart Failure
Primary: The Primary Endpoint is Success at 180 Days Which is Defined as Alive on the Originally Implanted HeartWare® LVAD or Transplanted or Explanted for Recovery. Patient Must…
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
N/A N=200 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Composite Endpoint — 46; 11 percentage of participants — p=0.00000025
N/A N=194 Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Survival — 112; 6; 18; 19 participants
N/A N=446 The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial
Chronic Heart Failure
Primary: Stroke-Free Survival Probability for 2 Years Post Implant — 55.4; 59.1 Probabillity — p=0.0110
N/A N=610 REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
Phase 3 N=93 The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume Index — -4.0; -2.0 ml/m^2 — p=0.19
N/A N=197 Model 4396 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Safety (Subjects Without a Model 4396 Lead Related Complication) — 155 participants
Phase 4 N=365 EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
Heart Failure
Primary: Change in NT-proBNP — 0.14; 0.19 unitless — p=0.45
N/A N=90 Model 4296 Left Ventricular (LV) Lead Study
Heart Failure
Primary: Number of Participants With Left Ventricular (LV)Lead Related Complications — 1 participants
N/A N=84 Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial
Heart Failure
Primary: Distribution of "Improved", "Unchanged" and "Worsened" Patients as Defined Per M. Packer's Clinical Composite Score — 11; 7; 10; 16 participants
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
N/A N=6 Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan
Heart Failure
Primary: Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days — 6 Participants
N/A N=101 Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
Heart Failure
Primary: Six Minute Hall Walk (6MHW) Distance — -44.9; 69.7 meters — p=0.001
N/A N=1,820 MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy
Tachycardia · Congestive Heart Failure
Primary: Mortality From Any Cause or First Heart Failure (HF) Event — 901; 543; 188; 188 Participants — p=< 0.001
N/A N=918 Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Atrioventricular Block · Heart Diseases
Primary: Mortality, Heart Failure-related Urgent Care Visits, or Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI) — 160; 191; 93; 136 participants…
Phase 2 N=25 Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement
Heart Failure
Primary: Safety of Cell Delivery — 1; 0 adverse events
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
Phase 3 N=188 Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Phase 2 N=122 Interventricular Delay of Lumax HF-T for Heart Failure
Congestive Heart Failure
Primary: Percentage of Subjects Classified as "Not Worsened" for Changes in the Minnesota Living With Heart Failure Questionnaire and Six-minute Walk Distance Between Periods of…
N/A N=60 Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure
Heart Failure
Primary: Change in Peak Oxygen Uptake (VO2) During Maximal Effort Exercise Stress Test According to Ejection Fraction Subgroups — 1.5; -0.5; 2.0; -1.0 percentage of change in…
N/A N=465 A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)
Chronic Heart Failure
Primary: Number of Participants With Neurologic Injury — 45; 19 Participants — p=0.1444
N/A N=15 An Assessment of Dual Site Left Ventricular Endocardial Pacing
Atrial Fibrillation · Ventricular Tachycardia · Heart Failure
Primary: Acute Haemodynamic Response to Dual Left Ventricular Pacing — 3.7 % difference — p=<0.05
N/A N=187 Predictors of Response to Biventricular Pacing in Heart Failure
Heart Failure, Wide QRS Complex
Primary: Minnesota For Living With Heart Failure Questionnaire — 31; 24 units on a scale
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
N/A N=1,685 MOMENTUM 3 Continued Access Protocol
Advanced Refractory Left Ventricular Heart Failure
Primary: Event-Free Survival — 1320 Participants
Phase 3 N=3,834 Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
Heart Failure
Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…